Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Emerging Therapies
First-in-Human CAR T-Cell Trial Demonstrates Activity in Multiple Myeloma
By
Dana Taylor
Emerging Therapies
,
Hematologic Malignancies
,
Multiple Myeloma
,
Personalized Medicine
March 2016, Vol 7, No 2
Chimeric antigen receptor (CAR) T-cell therapy has been striking in various hematologic malignancies, and for the first time this treatment approach is being evaluated in multiple myeloma.
Read Article
Inotuzumab Ozogamicin Shows Promise in Older Patients with Acute Lymphoblastic Leukemia
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
March 2016, Vol 7, No 2
Elderly patients with Philadelphia-negative B-cell acute lymphoblastic leukemia (ALL) have overall poor outcomes with current therapies. Results of a new study presented at ASH 2015 suggest that frontline treatment with the investigational antibody-drug conjugate inotuzumab ozogamicin in combination with deintensified chemotherapy is a good option for older patients with this disease.
Read Article
Atezolizumab, a PD-L1 Inhibitor, Shows Impressive Results in Metastatic Urothelial Cancer
By
Charles Bankhead
Emerging Therapies
,
Personalized Medicine
March 2016, Vol 7, No 2
Patients with previously treated metastatic urothelial cancer had response rates that exceeded historical standards when treated with an investigational immunotherapeutic agent, updated results of a large phase 2 clinical trial showed. Treatment with the PD-1 ligand 1 (PD-L1) inhibitor atezolizumab led to an overall response rate of 15% in 311 patients, including a 26% rate among patients who had the highest levels of PD-L1 expression. Historical data have demonstrated response rates of about 10% for second-line therapy and beyond.
Read Article
Promising Locoregional Therapies for Hepatocellular Carcinoma and Metastatic CRC
By
Walter Alexander
Emerging Therapies
,
Personalized Medicine
December 2015, Vol 6, No 11
Barcelona, Spain—Locoregional therapies for hepatocellular carcinoma and for colorectal cancer (CRC) metastases to the liver continue to demonstrate promising outcomes in clinical trials, according to findings presented at the 2015 European Society for Medical Oncology World Congress on Gastrointestinal Cancer.
Read Article
Significant Benefits Seen with 2 New Options for Patients with Renal-Cell Carcinoma
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
November 2015, Vol 6, No 10
Vienna, Austria—Patients with advanced, pretreated renal-cell carcinoma (RCC) who have limited treatment options got good news from 2 important practice-changing trials, CheckMate 025 and METEOR, which were presented as late-breaking abstracts at the 2015 European Cancer Congress (ECC). CheckMate 025 showed a survival benefit for nivolumab (Opdivo) over standard therapy with everolimus (Afinitor) in patients with previously treated advanced RCC. This is the first trial to show a survival benefit for an immune checkpoint inhibitor after standard therapy has failed. METEOR showed that cabozantinib (Cometriq) nearly doubled progression-free survival (PFS) compared with standard everolimus in patients with advanced RCC whose disease progressed with previous vascular endothelial growth factor (VEGF) receptor (VEGFR)-targeted therapy.
Read Article
Everolimus, 177Lu-DOTATATE Potentially 2 Practice-Changing Options in NETs
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
November 2015, Vol 6, No 10
“Everolimus is the first targeted agent to show robust antitumor activity with acceptable tolerability across a broad spectrum of NETs,” said James C. Yao, MD.
Read Article
Using Genetics to Guide Pembrolizumab Therapy in CRC
By
Dana Taylor
Emerging Therapies
,
Personalized Medicine
October 2015, Vol 6, No 9
The treatment of patients with colorectal cancer (CRC) may benefit from immunotherapy with anti–PD-1 agents, based on results of a recent study using pembrolizumab (Keytruda).
Read Article
NEXT Study: Biosimilar Filgrastim an Effective Alternative for Chemotherapy-Induced Neutropenia
By
Meg Barbor, MPH
Emerging Therapies
,
Personalized Medicine
,
Biosimilars
October 2015, Vol 6, No 9
Copenhagen, Denmark—Biosimilar filgrastim (Nivestim; Hospira), which was approved earlier this year by the European Commission but not yet by the FDA, showed effectiveness for the treatment of neutropenia and febrile neutropenia (FN) in patients undergoing cytotoxic chemotherapy for solid tumors and hematologic malignancies, according to a study presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology meeting.
Read Article
Atezolizumab: Another Immunotherapy for Lung Cancer?
By
Phoebe Starr
Emerging Therapies
,
Immunotherapy
,
Personalized Medicine
October 2015, Vol 6, No 9
Vienna, Austria—Immunotherapy is poised to become a game changer for patients with non–small-cell lung cancer (NSCLC).
Read Article
“Designer Drug” Rociletinib Shows Encouraging Results in Patients with NSCLC and T790M Mutation
By
Alice Goodman
Emerging Therapies
,
Personalized Medicine
September 2015, Vol 6, No 8
Boston, MA—Rociletinib, a specially engineered third-generation
EGFR
inhibitor, is accumulating an impressive track record in early studies of non–small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the
T790M
mutation, a heretofore patient population with unmet needs.
T790M
, the most common mutation associated with resistance to first-line
EGFR
-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs.
Read Article
Page 5 of 6
1
2
3
4
5
6
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma